Noemi Reguart: Lenvatinib plus pembro in pretreated B3-thymoma and thymic carcinoma by Jordi Remon

Noemi Reguart shared a post on X:

“ESMO 2024 – Jordi Remon elegantly presenting PECATI phase 2 lenvatinib plus pembro in pretreated B3-thymoma and thymic carcinoma. Primary endpoint met 5-mo PFS 88%. Promising 12-mo OS 85%. Higher dose intensity associated with better outcomes. Manageable safety BUT irAE 14%.”

Source: Noemi Reguart/X

Noemi Reguart is a Medical Oncologist at Hospital Clinic Barcelona. Prof. Reguart’s work focuses on translational genomics and targeted therapies in lung cancer. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. She is an active member of several international organizations including the Lung Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC).